Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Sales Pitch: How To Finish Weak vs Strong

Questioner - And Chris, if your next bit of data comes out and it's positive and the FDA says yeah you've got emergency approval what does that mean? How quickly..does that mean it goes global?

CEO -

Positive data Phase 2b, we've worked with the FDA. If we do get emergency use approval, we have been working on an immediate supply of the drug where I have confidence that we've dealt with that and we would start making the drug available. Again, if it's a US FDA Emergency Use Approval that means that it can be accessed in the US, but I would probably suspect other governments would be reaching out or we would reach out, Canada, Europe, and start making the drug available. From a use perspective depending on where we see the data, is it as Mark said, is it really helping the very sick. Uh right now our study is uh to enroll in the study you have to be hospitalized, confirmed covid and on oxygen. So that's a much smaller percentage of the population. So we need less drug. So I would think it would just be a roll out uh um and it would just depend on how long it takes for for health institutions and governments to reach out and say we'd like to access it and and we'll try to respond to that.

Questioner - I'm going to give the last word I think to Dr. Mark Williams just to wrap this up for us. Just to leave us with something a nibble that we can digest uh regarding Algernon Pharmaceuticals and this trial that's going on right now.

Dr. Mark Williams -

Again, just to reiterate uh this is interim data and there's always caution that needs to be taken with that. Uh the numbers again we're looking at a smaller subgroup of of the overall patients. Uh that data there's lots of endpoints to read out. Um and if any of them look positive that could give us the signal that this drug really is active in in patients. So uh I as long as everyone I think has waited with baited breath to find out what that data looks like and uh we'll make our decisions from there. It's it's clear that we still have a need for agents and uh we'll see if our agent is uh additive to existing therapy. That's part of the study as well. Uh most drugs are looking like they have to be combined with some of the existing therapies. So we'll have to look at it in that context. As Steve Palmer and other people pointed out this was really uh not our initial focus. So there's still our IPF trial to run and there's still lot's to lot's left in the company and you know we hopefully early of next year there'll be even more to come out that will get peoples attention. So uh again stay tuned. I think it's going to be a very interesting first quarter for this company.

Can you see the difference?

GL2ALL@AGNPF

M$